ScienceDriven
Explorer
China’s first and only weight-loss formulation of semaglutide for injection has been approved for the treatment of metabolic-associated steatohepatiti
Does the approval, which does not cover fatty liver disease indications, indicate that the technical review has been completed and the product is improving? Going forward, we’ll be able to use it wherever we go.
Does the approval, which does not cover fatty liver disease indications, indicate that the technical review has been completed and the product is improving? Going forward, we’ll be able to use it wherever we go.